IBM Stock: Buy or Sell? Price Target & Forecast

Analyses / IBM

IBM International Business Machines Corp As of Sep 11, 2026

$234.02

Dividend-yielding tech bellwether down 2.5% today; mixed near-term, watchlist-level positioning.

Setup: value_with_dividend_income Confidence: 62 Horizon: 3-6 months Risk: medium Category: Large Cap Technology

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals IBM's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Steady 4.3% dividend yield; insider buying outpacing selling 3:1 (685k vs 285k shares); P/E 20.9x below historical avg; 15.7% net margin + 58% gross margin suggest pricing power; quantum computing (Zacks mention) may drive strategic premium if capex deployed effectively.

▼ Bear Case

Down 29.6% from 52w high ($332); slow 3.7% revenue growth vs 4.1% 5Y avg; forward P/E 21.2x near current, little EPS growth tailwind priced in; quick ratio 0.87 signals tight liquidity; large cap inertia makes repositioning capital-intensive.

Valuation

FAIRLY PRICED with INCOME APPEAL — score 65/100

P/E 20.9x near forward 21.2x; both sit slightly below S&P 500 median (~22x). P/B 8.5x is elevated for a slow-growth tech name (revenue +3.7% YoY). However, 4.3% dividend yield + 15.7% net margin + insider buying suggest market is pricing a moderate recovery scenario, not a distressed or speculative one. Price-to-FCF 19.6x is reasonable for a large-cap tech compounder.

Technical Levels

Support · $225.00 (10-day MA + recent session low) · $210.00 (Recent 52w low breakout zone ($199 is 52w low))

Resistance · $242.00 (Today's high; short-term resistance) · $265.00 (3-month target; psychological 52w midpoint) · $290.00 (Bull-case target; multiple expansion zone)

RSI: unavailable

Financial Health

Score 65/100. Liquidity tighter than ideal (current & quick ratios both <1.0), suggesting IBM may have more current liabilities or less liquid assets than typical large cap; monitor for working-capital stress in downturn. Dividend appears sustainable at 59% payout, but limited dry powder for large acquisitions or shareholder buybacks. Debt structure unknown; full credit assessment requires balance sheet detail.

Catalysts

Q4 2024 Earnings (anticipated early 2025)	~4–8 weeks	high
AI/Quantum Strategic Update or Product Launch	unknown; Zacks coverage suggests analyst interest building	medium
Dividend Decision / Capital Allocation Comment	Earnings call or investor day	medium
Margin Expansion or Contraction Trend	quarterly results	medium

Risk Flags

Current ratio 0.96 below 1.0 — monitor working capital if revenue slows further

PEG ratio unavailable — cannot assess growth-adjusted valuation; 12% 5Y EPS growth is modest for tech

Market cap is $220.5B; concentrated position risk in portfolio if > 3% allocation

Dividend yield 4.3% + payout ratio 59% leaves modest reinvestment; dividend cut risk if earnings decline

News today is sector-level (quantum, Accenture comp); no IBM-specific positive catalyst visible in recent headlines

See IBM's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock IBM free →

More Analyses

MSFT

Microsoft Corp

DELL

Dell Technologies Inc

CRM

NVDA

AAPL

TSLA

IBM FAQ

Is IBM a buy right now?

International Business Machines Corp's current read is a value_with_dividend_income setup with 62 confidence over a 3-6 months horizon. Valuation: FAIRLY PRICED with INCOME APPEAL. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is IBM overvalued?

FAIRLY PRICED with INCOME APPEAL (valuation score 65/100). P/E 20.9x near forward 21.2x; both sit slightly below S&P 500 median (~22x). P/B 8.5x is elevated for a slow-growth tech name (revenue +3.7% YoY). However, 4.3% dividend yield + 15.7% net margin + insider buying suggest market is pricing a moderate recovery scenario, not a distressed or speculative one. Price-to-FCF 19.6x is reasonable for a large-cap tech compounder.

What are the risks of buying IBM?